Form 4: Kyverna Therapeutics Executive Granted Stock Options

Kyverna Therapeutics' Chief Medical & Development Officer, Naji Gehchan, was granted stock options for 425,000 shares.

Summary

• Naji Gehchan, the Chief Medical & Development Officer of Kyverna Therapeutics, was granted stock options for 425,000 shares.
• The options have an exercise price of $3.29 per share.
• The options vest over a period of four years, with 25% vesting on January 22, 2026, and the remaining 75% vesting monthly thereafter.
• The options expire on January 22, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The granting of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of compensation for executives in the biotechnology industry, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotech industry for executive compensation.
• The vesting schedule of four years with a one-year cliff is also typical for such grants.
• The exercise price of $3.29 is not directly comparable without knowing the current market price of the stock, but is a common practice to set the exercise price at or above the market price at the time of the grant.

Stakeholder Impact

• Shareholders may view this positively as it incentivizes the executive to increase the company's value.
• Employees may see this as a sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, insider trading, Kyverna Therapeutics, biotechnology, vesting